EU Approves Brainsway Device for Chronic Pain Application

Brainsway Ltd., a Jerusalem, Israel-based company, has received CE Mark approval for its Deep TMS system to treat neuropathic chronic pain. The device will be released in the European Union as well as certain states in Asia and South America that recognize the CE Mark.

“Neuropathic pain is the sixth indication for which Deep TMS has achieved CE Mark approval,” said Uzi Sofer, CEO of Brainsway. “Previous CE Marks were for clinical depression, bi-polar disorder, schizophrenia (negative symptoms), Parkinson’s diseases and post-traumatic stress disorder. As our therapeutic pipeline continues to expand, it is very exciting to continue to bring proven new Deep TMS treatments to market.”

Transcranial magnetic stimulation (TMS) is a non-invasive technique that uses brief magnetic pulses to the brain. The pulses are generated by passing high currents through an electromagnetic coil placed adjacent to the patient’s scalp. Brainsway claims that with TMS there are no significant side effects, no systemic effects as one would find with drug therapies, and no need for hospitalization or anesthesia.

Brainsway develops Deep TMS systems exclusively, with the goal of using the tech ology to treat disorders such as addiction, schizophrenia, obesity, eating disorders, Parkinson’s disease, Alzheimer’s disease, autism and post-traumatic stress disorder.